Ibrahim Halil Sahin, MD

home / authors / ibrahim-halil-sahin-md

Articles

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

Seth Felder, MD;Jessica Frakes, MD;Manju George, PhD;Allison Rosen, MS;Ibrahim Halil Sahin, MD

May 15th 2024

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.

Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer

Ibrahim Halil Sahin, MD

November 14th 2022

Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD;Yan Lin, PhD;Greg Yothers, PhD;Peter C. Lucas, MD, PhD;Dustin Deming, MD;Thomas J. George, MD;Scott Kopetz, MD, PhD;Christopher H. Lieu, MD;Arvind Dasari, MD, MS

October 14th 2022

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.